JP2023529203A - ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法 - Google Patents

ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法 Download PDF

Info

Publication number
JP2023529203A
JP2023529203A JP2022575936A JP2022575936A JP2023529203A JP 2023529203 A JP2023529203 A JP 2023529203A JP 2022575936 A JP2022575936 A JP 2022575936A JP 2022575936 A JP2022575936 A JP 2022575936A JP 2023529203 A JP2023529203 A JP 2023529203A
Authority
JP
Japan
Prior art keywords
conjugate
antigen
peptide
ckp
binding polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529203A5 (https=
Inventor
ホイットニー ビンダー，
クレーグ ディー． ブランシェット，
マーティン エー． ダルウィーシュ，
ラミ ハヌーシュ，
シンシン カオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023529203A publication Critical patent/JP2023529203A/ja
Publication of JP2023529203A5 publication Critical patent/JP2023529203A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022575936A 2020-06-11 2021-06-10 ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法 Pending JP2023529203A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038075P 2020-06-11 2020-06-11
US63/038,075 2020-06-11
US202163151591P 2021-02-19 2021-02-19
US63/151,591 2021-02-19
PCT/US2021/036878 WO2021252803A1 (en) 2020-06-11 2021-06-10 Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Publications (2)

Publication Number Publication Date
JP2023529203A true JP2023529203A (ja) 2023-07-07
JP2023529203A5 JP2023529203A5 (https=) 2024-06-18

Family

ID=76744974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575936A Pending JP2023529203A (ja) 2020-06-11 2021-06-10 ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法

Country Status (12)

Country Link
US (1) US20240059755A1 (https=)
EP (1) EP4164693A1 (https=)
JP (1) JP2023529203A (https=)
KR (1) KR20230023727A (https=)
CN (1) CN115803063A (https=)
AU (1) AU2021289738A1 (https=)
BR (1) BR112022025227A2 (https=)
CA (1) CA3183808A1 (https=)
IL (1) IL298878A (https=)
MX (1) MX2022015651A (https=)
TW (1) TW202214307A (https=)
WO (1) WO2021252803A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023269666A1 (en) * 2022-05-13 2024-11-28 Kisbee Therapeutics, Inc. Apoe lipoprotein systems
CN121358763A (zh) * 2023-06-15 2026-01-16 Rnagene公司 包括载脂蛋白质或其片段的融合蛋白质和其用途
CN121293315A (zh) * 2025-09-26 2026-01-09 南开大学 纳米磷脂盘中bcma全长受体的构建方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311276A1 (en) * 2008-05-22 2009-12-17 Hoeprich Paul D Nanolipoprotein particles and related compositions, methods and systems
US20190307692A1 (en) * 2016-03-07 2019-10-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for improved drug loading
US20200108133A1 (en) * 2018-05-24 2020-04-09 Lawrence Livermore National Security, Llc Antigenic combinations against francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311276A1 (en) * 2008-05-22 2009-12-17 Hoeprich Paul D Nanolipoprotein particles and related compositions, methods and systems
US20190307692A1 (en) * 2016-03-07 2019-10-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for improved drug loading
US20200108133A1 (en) * 2018-05-24 2020-04-09 Lawrence Livermore National Security, Llc Antigenic combinations against francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 31, JPN6025016718, January 2020 (2020-01-01), pages 743 - 753, ISSN: 0005774751 *
FEBS LETTERS, vol. 413, JPN6025016717, 1997, pages 177 - 180, ISSN: 0005774752 *

Also Published As

Publication number Publication date
BR112022025227A2 (pt) 2023-01-03
AU2021289738A1 (en) 2022-12-15
MX2022015651A (es) 2023-01-16
CA3183808A1 (en) 2021-12-16
WO2021252803A1 (en) 2021-12-16
TW202214307A (zh) 2022-04-16
CN115803063A (zh) 2023-03-14
IL298878A (en) 2023-02-01
US20240059755A1 (en) 2024-02-22
KR20230023727A (ko) 2023-02-17
EP4164693A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
US20240059755A1 (en) Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
JP2024161539A (ja) 腫瘍関連抗原に対する三重特異性結合分子及びその使用
TWI637966B (zh) 用於部位專一性接合之抗體和抗體片段
US10472426B2 (en) Disulfide stabilized DVD-Ig molecules
AU2018266091B2 (en) Multispecific protein drug and library thereof, preparing method therefor and application thereof
US20210379153A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20210324041A1 (en) Combination therapies
EP4430086A1 (en) Sirp1a - and cd40l-based chimeric proteins
HK40089788A (zh) 纳米脂蛋白-多肽缀合物和组合物、系统以及其使用方法
JP7386318B2 (ja) 体液性免疫抑制疾患の治療のための、体液性免疫抑制因子の拮抗薬の組成物および使用
JPWO2019176866A1 (ja) ウテログロビンを構造基盤とする二重特異性ポリペプチド
WO2024026340A1 (en) Combination therapy for treatment of ovarian cancer
Collins Development of bispecific antibody mimetics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420